201 related articles for article (PubMed ID: 23284638)
1. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Pfister TD; Hollingshead M; Kinders RJ; Zhang Y; Evrard YA; Ji J; Khin SA; Borgel S; Stotler H; Carter J; Divelbiss R; Kummar S; Pommier Y; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2012; 7(12):e50494. PubMed ID: 23284638
[TBL] [Abstract][Full Text] [Related]
2. Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Kinders RJ; Hollingshead M; Lawrence S; Ji J; Tabb B; Bonner WM; Pommier Y; Rubinstein L; Evrard YA; Parchment RE; Tomaszewski J; Doroshow JH;
Clin Cancer Res; 2010 Nov; 16(22):5447-57. PubMed ID: 20924131
[TBL] [Abstract][Full Text] [Related]
3. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
[TBL] [Abstract][Full Text] [Related]
6. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
Pfister TD; Reinhold WC; Agama K; Gupta S; Khin SA; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):1878-84. PubMed ID: 19584232
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
[TBL] [Abstract][Full Text] [Related]
9. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
Ji J; Kinders RJ; Zhang Y; Rubinstein L; Kummar S; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2011; 6(10):e26152. PubMed ID: 22028822
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
11. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
12. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
[TBL] [Abstract][Full Text] [Related]
13. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
[No Abstract] [Full Text] [Related]
14. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
[TBL] [Abstract][Full Text] [Related]
15. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
[TBL] [Abstract][Full Text] [Related]
16. Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors.
Seol Y; Zhang H; Agama K; Lorence N; Pommier Y; Neuman KC
Mol Cancer Ther; 2015 Nov; 14(11):2552-9. PubMed ID: 26351326
[TBL] [Abstract][Full Text] [Related]
17. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
[TBL] [Abstract][Full Text] [Related]
18. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Pommier Y; Cushman M
Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
[TBL] [Abstract][Full Text] [Related]
20. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]